Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Alan S. Wayne, MD, Gerard Michel, MD, Daniel W. Lee, MD, André Baruchel, MD, Sonali Chaudhury, MD, Patrick A. Brown, MD, Michelle Hermiston, MD PhD, Joerg Krueger, MD, Tong Shen, PhD, Kristy Tailford, PhD, Behzad Kharabi Masouleh, MD

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-137233

Published: 2020

Journal Articles

Infectious Complications Associated with CAR T-Cell Therapy

Lekha Mikkilineni, MD, Shilpa Shahani, MD, Bonnie Yates, NP, Seth M. Steinberg, PhD, Tara Palmore, MD, Veronique Nussenblatt, MD, Daniel W. Lee, MD, Rosandra N. Kaplan, MD, Crystal L. Mackall, MD, Terry J. Fry, MD, Juan Gea-Banacloche, MD, Theresa Jerussi, James N. Kochenderfer, MD, Nirali N. Shah, MD

Blood (2019) 134 (Supplement_1): 4449.

https://doi.org/10.1182/blood-2019-131170

Published: 2019

Journal Articles

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Robbie G. Majzner, MD, Skyler P. Rietberg, Louai Labanieh, Elena Sotillo, PhD, Evan W. Weber, PhD, Rachel C. Lynn, PhD, Johanna L. Theruvath, MD, Constance M. Yuan, MD PhD, Peng Xu, MD, Sang M. Nguyen, BS, Nirali N. Shah, MD, Maryalice Stetler-Stevenson, MD PhD, Terry J. Fry, MD, Daniel W. Lee, MD, Crystal L. Mackall, MD

Blood (2018) 132 (Supplement 1): 963.

https://doi.org/10.1182/blood-2018-99-115558

Published: 2018

Journal Articles

Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia

Daniel W. Lee, MD, Maryalice Stetler-Stevenson, MD PhD, Marianna Sabatino, MD, Constance Yuan, MD PhD, Terry J Fry, MD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, Hua Zhang, PhD, Ling Zhang, Nick Tschernia, BS, Yongzhi Cui, MD PhD, Steven Feldman, PhD, James N Kochenderfer, MD, Steven A. Rosenberg, MD, PhD, David F. Stroncek, MD, Alan S. Wayne, MD, Crystal L Mackall, MD

Blood (2014) 124 (21): 381.

https://doi.org/10.1182/blood.V124.21.381.381

Published: 2014

Journal Articles

Novel Antigen-Specific Expansion of T Cells Transduced with a CD19 Chimeric Antigen Receptor

Daniel W. Lee, MD, James N Kochenderfer, Christoph Rader, PhD, Rimas J Orentas, PhD, Crystal L Mackall, MD

Blood (2010) 116 (21): 3262.

https://doi.org/10.1182/blood.V116.21.3262.3262

Published: 2010

Journal Articles

SHIP1 Is a Novel Tumor Suppressor in Late-Stage Myelodysplastic Syndromes and Is Silenced by Mir-210 and Mir-155.

Daniel W. Lee, MD, Carlos E. Bueso-Ramos, MD, Martin Carroll, MD, Zak Whichard, BA, Yanming Feng, PhD, Peter Stein, Samuel A. Jensen, BS, Steven M. Kornblau, MD, Seth J. Corey, MD, MPH

Blood (2009) 114 (22): 3824.

https://doi.org/10.1182/blood.V114.22.3824.3824

Published: 2009

Journal Articles

Multi-Scale Analysis of Granulopoiesis: A Bottoms-Up Approach.

Daniel W. Lee, MD, Christopher Thompson, BS, Mandri N. Obeyesekere, PhD, Seth J. Corey, MD

Blood (2007) 110 (11): 3854.

https://doi.org/10.1182/blood.V110.11.3854.3854

Published: 2007

Journal Articles

Abnormal PI 3-Kinase Activity Due to Increased Lyn with Decreased PTEN and Absent SHIP in Bone Marrow Cells from Patients with Myelodysplastic Syndromes.

Daniel W. Lee, MD, Quan-Sheng Zhu, MD, PhD, Sonali Rudra, BS, Elizabeth J. Shpall, MD, Steven Kornblau, MD, Seth J. Corey, MD, MPH

Blood (2005) 106 (11): 3446.

https://doi.org/10.1182/blood.V106.11.3446.3446

Published: 2005

Journal Articles

Disturbed Regulation and Activity of PI 3-Kinase Activity Due to Enhanced Lyn Kinase but Decreased Ship-1 and Gab2 Levels in Patients with Myelodysplastic Syndrome.

Daniel W. Lee, MD, Quan-Sheng Zhu, MD, PhD, Gus Zamora, BS, Ogonna Nwawka, BS, Elizabeth J. Shpall, MD, Steven K. Kornblau, MD, Seth J. Corey, MD, MPH

Blood (2004) 104 (11): 3423.

https://doi.org/10.1182/blood.V104.11.3423.3423

Published: 2004

NARROW

ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Infectious Complications Associated with CAR T-Cell Therapy

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia

Novel Antigen-Specific Expansion of T Cells Transduced with a CD19 Chimeric Antigen Receptor

SHIP1 Is a Novel Tumor Suppressor in Late-Stage Myelodysplastic Syndromes and Is Silenced by Mir-210 and Mir-155.

Multi-Scale Analysis of Granulopoiesis: A Bottoms-Up Approach.

Abnormal PI 3-Kinase Activity Due to Increased Lyn with Decreased PTEN and Absent SHIP in Bone Marrow Cells from Patients with Myelodysplastic Syndromes.

Disturbed Regulation and Activity of PI 3-Kinase Activity Due to Enhanced Lyn Kinase but Decreased Ship-1 and Gab2 Levels in Patients with Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only